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ABSTRACT 
An ocular insert represents an advanced technology in eye disease therapy. Designing and development of an ocular insert is a 
challenge ever faced by Pharmaceutical researchers or manufacturer. In the ophthalmology; eye drop have ever found to be an easy 
remedy from the administration point of view. In case of conventional dosage forms the fast precorneal loss of drug has been a major 
difficulty. To improve ocular drug bioavailability, there are significant guidelines have been directed towards newer drug delivery 
systems for ophthalmic administration. By means of ocular insert, the researcher has always taken efforts to release the drug at 
controlled rate to avoid frequent administration of drug. The ocular insert consist of controlled, delayed or sustained release 
biodegradable implantable components of different material in multiple layers. The inserts can be classified in various classes like 
Insoluble, soluble or biodegradable as per its solubility. The release of drug from the insert depends upon the diffusion, osmosis, and 
bioerosion of the drug. 
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1. INTRODUCTION 
Delivery of drug to the eye has remained as one of the 
most challenging task for pharmaceutical scientists. The 
intraocular bioavailability of the drug through 
conventional eye drops is very poor due to factors such 
as naso-lachrymal drainage, lacrimation, and drug 
dilution with tear fluid, tear turnover and conjuctival 
absorption.
1
 binding of drugs to protein also contributes 
to loss of drugs through the precorneal parallel 
elimination loss pathway. Consequently, only a small 
amount of (1-3%) drug actually penetrates the cornea 
and reaches the intraocular tissue.
2,3 
A sincere attempt to prolong the contact of ophthalmic 
drug with cornea can improve its efficiency. This can be 
fulfilled by incorporating viscosity enhancing agent in 
eye drops or by using water insoluble ointment base in 
ophthalmic formulation which increase the drug content 
with cornea. Unfortunately these attempts have shown 
limited improvement in drug cornea contact than 
conventional eye drop solution, but consistent drug 
availability is still a challenging task to be achieved to 
avoid repeated medication throughout the day. To solve 
this problem the search for finding the alternative 
method for ocular drug delivery system has stimulated. 
Now days much of the work recently devoted to ocular 
inserts, which serves as the platform for the release of 
one or more active substances. It has become clear, 
however that the development of an ocular insert that 
reliably combines controlled release with absence of any 
irritation to the patient.
4
 Is an area of thirst Ocular insert 
are the new drug delivery systems which are prepared in 
such a way that they release the drug at predetermined 
and predictable rates which eliminates the problem of 
the frequent administration of the drug. Ophthalmic 
inserts are defined as sterile preparations, with a thin, 
multilayered, drug‐impregnated, solid or semisolid 
consistency devices placed into cul‐de‐sac or conjuctival 
sac and whose size and shape are especially fabricated 
for ophthalmic application. Ophthalmic inserts offer 
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many advantages over conventional dosage forms such 
as increased ocular residence, sustained release, accurate 
dosing, and reduced dose frequency. 
History of ocular inserts 
The first solid medication (precursors of the present 
insoluble inserts) was used in the 19th century, which 
consisted of squares of dry filter paper, previously 
impregnated with dry solutions (e.g., atropine sulphate, 
pilocarpine hydrochloride). Small sections were cut and 
applied under eyelid. Later, lamellae, the precursors of 
the present soluble inserts, were developed. They 
consisted of glycerinated gelatin containing different 
ophthalmic drugs. Glycerinated gelatin ‘lamellae’ were 
present in official compendia until the first half of the 
twentieth century. However, the use of lamellae ended 
when more stringent requirements for sterility of 
ophthalmic preparations were enforced. Nowadays, 
growing interest is being observed for ophthalmic 
inserts
.5
 
OCULAR PHARMACOKINETICS  
The drug pharmacokinetics from the eye follows the 
following paths  
 Transcorneal permeation from the lacrimal fluid 
into the anterior chamber.  
 Non-corneal drug permeation across the conjunctiva 
and sclera into the anterior uvea.  
 Drug distribution from the blood stream via blood-
aqueous barrier into the anterior chamber.  
 Elimination of drug from the anterior chamber by 
the aqueous humor turnover to the trabecular 
meshwork and sclemm's canal.  
 Drug elimination from the aqueous humor into the 
systemic circulation across the blood-aqueous 
barrier.  
 Drug distribution from the blood into the posterior 
eye across the blood-retina barrier.  
 Intra vitreal drug administration.  
 Drug elimination from the vitreous via Eg. Posterior 
route across the blood-retina barrier.  
 Drug elimination from the vitreous via anterior 
route to the posterior chamber.
6
   
Mechanism of ocular drug absorption 
Topical delivery into the cul-de-sac is, by far, the most 
common route of ocular drug delivery. Absorption from 
this site may,
7, 8
  
1. Corneal  
2. Non-corneal 
Merits of ocular inserts
9, 10
 
1. The side effects due to the pulsed dosing of 
conventional dosage form can be overcome by 
using ocular insert.  
2. Provides sustained and controlled drug delivery.  
3. Increases the ocular bioavailability of drug by 
increasing the corneal contact time 
4. Provides targeting within the ocular globe so as to 
prevent the loss to other ocular tissues.  
5. Circumvent the protective barriers like drainage, 
lacrimation and conjunctival absorption.  
6. Provide comfort, better compliance to the patient 
and to improve therapeutic performance of drug.  
7. Provide better housing of delivery system. 
8. Increased shelf life with respect to aqueous 
solutions. 
Demerits of ocular insert
11, 12, 13
 
1. A capital demerit of ocular inserts resides in their 
‘solidity’, i.e., it is experienced as a foreign body in 
the eye by the patient. 
2. Their movement around the eye, in rare instances, 
the simple removal is made more difficult by 
unwanted migration of the insert to the upper 
fornix. 
3. The occasional inadvertent loss during sleep or 
while rubbing the eyes, 
4. Their interference with vision, and difficult 
placement of the ocular inserts (and removal, for 
insoluble types). 
Classification of ocular inserts: 
Ocular insert are mainly divided in three classes. 
1. Insoluble ocular inserts. 
2. Soluble ocular inserts 
3. Bioerodible ocular inserts 
Insoluble ophthalmic inserts 
The insoluble inserts have been classified into three 
groups:-  
i. Diffusion systems  
ii. Osmotic systems  
iii. Hydrophilic contact lenses.  
The first two classes include a reservoir in contact with 
the inner surface of the rate controller and supplying 
drug thereto. The reservoir contains a liquid, gel, 
colloid, semisolid, solid matrix or a carrier-containing 
drug homogeneously or heterogeneously dispersed or 
dissolved therein. Carriers can be made of hydrophobic, 
hydrophilic, organic, inorganic, naturally occurring or 
synthetic material. The third class includes the contact 
lenses. The insolubility of these devices is their main 
disadvantage, since they have to be removed after use.
14
 
Diffusion inserts 
The diffusion systems are comprised of a central 
reservoir of drug enclosed in semi permeable or micro 
porous membranes, which allow the drug to diffuse 
through the reservoir at a precisely determined rate. The 
drug release from such a system is controlled by the 
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lachrymal fluid permeating through the membrane until 
it form an adequate internal pressure to drive the drug 
out of the reservoir. The drug delivery rate is controlled 
by diffusion through the membrane, which can be 
controlled.
15
  
Osmotic inserts 
The osmotic inserts are generally divided into two types, 
in first type the central part covered by a peripheral part. 
The first central part can be composed of a single 
reservoir or of two distinct compartments. In first Type, 
it is composed of a drug with or without an additional 
osmotic solute dispersed through a polymeric matrix, so 
that the drug is covered by the polymer as discrete small 
deposits. In the second type, the drug and the osmotic 
solutes are placed in two separate compartments, the 
drug reservoir being covered by an elastic impermeable 
membrane and the osmotic solute reservoir is covered 
by a semi permeable membrane. The peripheral part of 
these osmotic inserts comprises in all cases a covering 
film made of an insoluble semi permeable polymer. The 
tear fluid diffuses into peripheral deposits through the 
semi permeable polymeric membrane and wets them to 
induce their dissolution. The solubilized deposits 
generate a hydrostatic pressure against the polymer 
matrix which causes bursting of matrix. the Drug is then 
released through the matrix. This corresponds to the 
osmotic part characterized by zero order drug release 
profile.
16
 
Table 2:  Components of osmotic inserts 
Water permeable 
matrix 
Ethylene: vinyl esters copolymers, Divers: plasticized polyvinyl chloride (PVC), polyethylene, 
cross-linked, Poly vinyl pyrrolidone(PVP) 
Semi permeable 
membrane 
Cellulose acetate derivatives, Divers: Ethyl vinyl acetate (EVA), polyesters of acrylic and 
methacrylic acids (Eudragit ®). 
Osmotic agents 
Inorganic: magnesium sulfate, sodium chloride, potassium phosphate dibasic sodium carbonate 
and sodium sulfate.  
Organic: calcium lactate, magnesium succinate and tartaric acid. 
Carbohydrates: Sorbitol, mannitol, glucose and sucrose. 
 
Soft contact lenses 
These are shaped structure made up of a covalently cross 
linked hydrophilic or hydrophobic polymer that forms a 
three-dimensional network or matrix capable of 
retaining water, aqueous solution or solid components. 
When a hydrophilic contact lens is soaked in a drug 
solution, it absorbs the drug, but does not give a delivery 
as precise as that provided by other non-soluble 
ophthalmic systems. The drug release from such a 
system is generally very fast at the beginning and then 
declines exponentially with time. The release rate can be 
decreased by incorporating the homogenous mixture of 
drug during the manufacture or by adding a hydrophobic 
component.
17
  
Soluble Ophthalmic inserts 
Soluble inserts correspond to the oldest class of 
ophthalmic inserts. They offer the great advantage of 
being entirely soluble so that they do not need to be 
removed from their site of application, thus limiting the 
interventions to insertion only.
18
 
Types of soluble ophthalmic inserts 
a) Based on natural polymers e.g. collagen.  
b) Based on synthetic or semi synthetic polymers 
The therapeutic agent is preferably absorbed by soaking 
the insert in a solution containing the drug, drying and 
rehydrating it before use on the eye. The amount of drug 
loaded will depend upon the amount of binding agent, 
and on the concentration of the drug solution into which 
the composite is soaked, as well as the duration of the 
soaking. 
The soluble ophthalmic inserts containing 
synthetic/semi synthetic polymer: Offers the additional 
advantages of being generally of a simple design. 
a. Based on products well adopted for ophthalmic use. 
b. Easily processed by conventional methods – slow 
evaporating extrusion, compression or    injection 
molding. 
The release of the drug from such system is by 
penetration of tears into the insert which induces release 
of the drug by diffusion and forms a gel layer around the 
core of the insert, this external gelification induces the 
further release, but still controlled by diffusion. The 
release rate, J, is derived from Fick’s law yields the 
following expression. 
J=AdkCS  L     
When A - Surface area of the membrane. 
        K – Diffusion coefficient of the drug 
        L – Membrane thickness 
        CS – Drug solubility in water 
        D – Diffusion coefficient of the ocusert membrane. 
Since all the terms on the right hand side of the above 
equation are constant, so is the release rate of the device. 
The other factors affecting drug release from these 
Ocuserts include: 
• Penetration of the inclusion. 
• Swelling of the matrix. 
• Dissolution of the drug and the polymers. 
• Relaxation of the polymeric chain. 
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The soluble insert made of cellulose derivatives can be 
sterilized by exposure to gamma radiation without the 
cellulose components being altered. A decreased release 
rate is obtained by using a component of the matrix a 
polymer normally used for enteric coatings or by 
introducing a suitable amount of hydrophobic polymer 
capable of diminishing the tear fluid penetration and 
thus decreasing the release of the drug without 
modifying the solubility of the insert when added in 
proper proportion.
19 
 
Table 3: Components Of Soluble Inserts Containing Synthetic Polymers 
Soluble synthetic 
polymers 
Cellulose derivatives –Hydroxypropyl cellulose methylcellulose, hydroxyethyl Cellulose and 
hydroxypropyl cellulose. 
Divers – Polyvinyl alcohol, ethylene vinyl acetate copolymer. 
Additives 
Plastisizer – Polyethylene glycol, glycerin, propylene glycol  
Enteric coated polymer –Cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate. 
Complexing agent – Polyvinyl pyrrolidone. 
Bioadhesives – Polyacrylic acids. 
 
A. Bio-erodible ocular inserts  
These inserts are formed by bio-erodible polymers (e.g., 
cross-linked gelatin derivatives, polyester derivatives) 
which undergo hydrolysis of chemical bonds and hence 
dissolution.
20,21
 The great advantage of these bio-
erodible polymers is the possibility of modulating their 
erosion rate by modifying their final structure during 
synthesis and by addition of anionic or cationic 
surfactants. A cross-linked gelatin insert was used by 
Attia et al.
22
 to increase bioavailability of 
dexamethasone in the rabbit eye. The dexamethasone 
levels in the aqueous humor were found to be four-fold 
greater compared to a dexamethasone suspension. 
However, erodible systems can have significantly 
variable erosion rates based on individual patient 
physiology and lachrimation patterns, while degradation 
products and residual solvents used during the polymer 
preparation can cause inflammatory reaction.The solid 
inserts absorb aqueous tear fluid and gradually erode or 
disintegrate. Then the drug is slowly leached from 
hydrophilic matrix. After completion of drug delivery 
bio-erodible ocular inserts are not needed to be removed. 
The marketed devices of erodible drug inserts are 
Lacriserts, SODI, and Minidisc. 
1. Lacrisert  
Lacriserts are hydroxyl propyl cellulose rod shaped 
device lack of preservative useful for dry eye syndrome. 
It weighs 5 mg and measures 12.7 mm in diameter with 
a length of 3.5 mm. Lacrisert is useful in treatment of 
keratitis whose symptoms are difficult to treat with 
artificial tear alone. It is inserted into cul-de-sac cavity 
where it absorbs water from conjunctiva and cornea, 
forms a hydrophilic film which stabilizes tear film for 
hydration and lubrication of cornea. It dissolves in 24 
hours.
6
 
2. SODI  
Soluble Ocular Drug Insert (SODI) is a small oval wafer 
developed for space pilots who could not use eye drops 
in weightless conditions. It is sterile thin film of oval 
shape made from acryl amide, N-vinyl pyrrolidone and 
ethylacrylate called as ABE. It weighs about 15-16 mg. 
It is used in treatment of glaucoma and trachoma. It is 
inserted into inferior cul-de-sac and gets wets and 
softens in 10-15 seconds. After 10-15 min film turns into 
a viscous polymer mass, after 30-60 minutes it turns into 
polymer solutions and delivers drug for about 24 
hours.
23
 
3. Minidisc  
The minidisc consists of a contoured disc with a convex 
front and concave back surface in contact with eyeball. 
It is like a miniature contact lens with a diameter of 4-
5mm. The minidisc is made up of silicone based pre-
polymer-α-bis (4-methacryloxy) butyl polydimethyl 
siloxane. Minidisc can be hydrophilic or hydrophobic to 
permit extend release of both water soluble and 
insoluble drugs
24
. 
4. Collagen shields  
Collagen shield basically consist of cross linked 
collagen, fabricated with foetal calf skin tissue and 
developed as a corneal bandage to promote wound 
healing. Tear fluid makes these devices soft and form a 
thin pliable film which is having dissolution rate up to 
10, 24 or 72 hours. Because of its structural stability, 
good biocompatibility and biological inertness, collagen 
film proved as a potential carrier for ophthalmic drug 
delivery system. Collagen ophthalmic inserts are 
available for delivery of drug to the eye.
25 
B. Non-Erodible Ocular Insert 
The Non-erodible ocular inserts include Ocusert, and 
Contact lens. 
1. Ocusert  
The technology used in this is an insoluble delicate 
sandwich technology. In ocusert drug reservoir is a thin 
disc of drug complex sandwiched between two 
transparent discs of micro porous membrane prepared 
from ethylene-vinyl acetate copolymer. The micro 
porous membranes permit tear fluid to penetrate into 
drug reservoir compartment to dissolve drug from 
complex. The sandwich technology which is used in 
ocular insert shown in figure 1.
26, 27
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Figure 1: Ocusert 
2. Contact lenses  
Contact lenses can absorb water soluble drugs when 
soaked in drug solutions. These drug saturated contact 
lenses are placed in eye for releasing drug for long 
period of time. The hydrophilic contact lenses can be 
used to prolong the ocular residence time of the 
drugs.
20,28,29
  
Mechanism of Drug Release from Ocular Inserts 
Diffusion 
In this mechanism, the drug is released continuously at a 
controlled rate through the membrane.  If the insert is 
formed of a solid non-erodible body having pores and 
drug is in a dispersed form, the drug release takes place 
via diffusion through the pores. Controlled release of the 
drug can be maintained by a gradual dissolution of the 
solid dispersed drug in the matrix, as a result of the 
inward diffusion of aqueous solutions. In a soluble 
device, true dissolution occurs mainly through polymer 
swelling. In swelling-controlled devices, the active agent 
is homogeneously dispersed in a glassy polymer. As 
glassy polymers are essentially drug-impermeable, no 
diffusion occurs through the dry matrix. When the insert 
is placed in the eye, water from the tear fluid begins to 
penetrate the matrix, swelling occurs, and consequently 
polymer chain relaxation occurs and drug diffusion takes 
place. The dissolution of the matrix, followed by the 
swelling process depends on the polymer structure. A 
linear amorphous polymer dissolves at a faster rate than 
a cross-linked or partially crystalline polymer.
30,31
 
Osmosis 
In the Osmosis mechanism, the insert is made of a 
transverse impermeable elastic membrane, which 
divides the interior of the insert into two compartments, 
first and second; the first compartment is surrounded by 
a semi-permeable membrane and the impermeable 
elastic membrane, and the second compartment is 
surrounded by an impermeable material and the elastic 
membrane. There is a drug release orifice in the 
impermeable membrane of the insert. The first 
compartment contains a solute that cannot pass through 
the semi-permeable membrane and the second 
compartment provides a reservoir for the drug, which is 
in liquid or gel form. When the insert is placed in the 
aqueous environment of the eye, water diffuses in the 
first compartment, which stretches the elastic membrane 
to expand the first compartment and contract the second 
compartment so that the drug is forced to come out 
through the drug release orifice.
31
 
Bioerosion 
In the bioerosion mechanism, the insert is comprised of 
a matrix of bioerodible material in which the drug is 
dispersed. Contact of the insert with the tear fluid results 
in controlled sustained release of the drug by bioerosion 
of the matrix. The drug is dispersed uniformly 
throughout the matrix, but it is believed that a more 
controlled release is obtained if the drug is superficially 
concentrated in the matrix. In truly erodible or E-type 
devices, the drug release is controlled by a chemical or 
enzymatic hydrolytic reaction that leads to polymer 
solubilization, or degrades to smaller, water-soluble 
molecules. These polymers may undergo bulk or surface 
hydrolysis, which displays zero order release kinetics; 
provided the devices maintain a constant surface 
geometry and the drug is poorly water soluble. 
Evaluation test for ocular inserts: 
1. Thickness 
2. Folding Endurance Test 
3. Surface pH 
4. Weight uniformity 
5. Drug content uniformity 
6. Tensile strength 
7. In vitro drug release study 
8. Ex vivo transcorneal permeability study 
9. Drug releasr kinetics 
10. Accelerated stability study. 
Thickness of film 
Film thickness is measured by using the Dial caliper at 
different points of the formulation and the mean value is 
calculated.
10
 
Folding Endurance  
Folding endurance was determined by repeatedly fold 
the film at the same place till breaking or first sign of 
breaking. The number of time the film could be folded at 
the same place without breaking gives the folding 
endurance value.
32
 
C. Surface pH    
The Dorzolamide inserts were allowed to swell in closed 
petridish at room temperature for 30 min in 1 ml of 
distilled water. The swollen device was removed and 
solution placed under digital pH meter to determine the 
surface pH.
33
 
D. Weight Uniformity  
From each batch (n = 3), inserts were taken and weighed 
individually using digital balance. The mean weights of 
the insert were recorded.
32
 
E. Drug Content Uniformity  
To check the uniformity of drug in insert, each insert 
was placed in a glass vial containing 10 ml of artificial 
tear fluid. The insert was dissolved by aid of a magnetic 
stirrer, solution was then filtered and 1 ml from filtrate 
was withdrawn and diluted up to 10 ml distilled water 
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and absorbance was measured by UV–Visible 
spectrophotometer.
32
         
F. Tensile strength 
Tensile strength of the prepared films was calculated 
according to the following equation.
34,35
 
Tensile strength =    N/ mm
2
 
i. e.      Breaking load N 
            Cross sectional area of the sample mm
2 
In vitro drug release study 
In vitro drug release from the different ocular inserts was 
studied by using franz diffusion cell and dialysis 
membrane. The dialysis membrane mimics corneal 
epithelium. The receptor compartment was filled with 
freshly prepared artificial tear fluid. 1.5 cm
2
 area of 
ocular film was placed on the dialysis membrane and 
opening of the donor compartment was sealed with a 
glass cover slip, while the receptor fluid was maintained 
at 37 ± 0.5ºC  with constant stirring, using magnetic 
stirrer. 1 ml sample was withdrawn from receptor 
compartment at various time intervals up to 6 h and was 
analyzed spectrophotometrically. Each sample 
withdrawn was replaced with equal volume of artificial 
tear fluid.
32
  
H. Ex vivo transcorneal permeation study 
Whole eye ball of goat was transported from local 
butcher shop to the laboratory in cold (4ºC) normal 
saline within 1 h of slaughtering the animal. The cornea 
was carefully excised along with 2–4 mm of surrounding 
scleral tissue and was washed with cold normal saline 
till the washing was free from proteins. Isolated cornea 
was mounted by sandwiching surrounding scleral tissue 
between clamped donor and receptor compartments of 
an all glass modified Franz diffusion cell in such way 
that its epithelial surface faced the donor compartment. 
The receptor compartment was filled with freshly 
prepared artificial tear fluid. 1.5cm
2
 area of ocular film 
was placed on the cornea and opening of the donor 
compartment was sealed with a glass cover slip, while 
the receptor fluid was maintained at 37 ± 0.5ºC with 
constant stirring, using magnetic stirrer. 1ml sample was 
withdrawn from receptor compartment at various time 
intervals up to 6 h and was analyzed 
spectrophotometrically. Each sample withdrawn was 
replaced with equal volume of artificial tear fluid.
34,35
 
I. Drug release kinetics 
Drug release mechanisms and kinetics are the two 
important characteristics of a drug delivery system in 
describing drug dissolution profile. To describe the 
kinetics of the drug release from optimised Ocular insert, 
mathematical models such as zero-order, first order, 
Higuchi, Hixson-Crowell and Korsmeyer-Peppas models 
were used. The criterion for selecting the most 
appropriate model was chosen on the basis of the 
goodness or fit test.  
J. Sterility testing as per I.P. 2014 
The test for sterility on the sterilized ocular insert was 
carried out by direct inoculation method. 
Culture media 
Alternate thioglycolate medium and soyabean casein 
digest medium was used as a culture medium for 
bacteria (S. aureus) and fungi (C. albicans) respectively. 
Media were prepared according to I.P.2014 and 20 ml 
was taken in boiling test tube, properly plugged with 
cotton and sterilized by autoclaving at 121ºC at 15 
lb/inch gauge pressure for 20 minutes. 
Inoculation and incubation  
Formulation was aseptically added in test tube 
containing respective media and simultaneously positive 
and negative control was prepared for each media. The 
inoculated culture media for bacteria and fungi were 
incubated at 30
o
C - 35
o
C and 20
o
C - 25
o
C respectively in 
incubator for not less than 14 days. 
K. Accelerated stability studies as per ICH 
Guidelines  
The accelerated stability studies are carried out to 
predict the degradation that occurs over prolonged 
periods of storage, at normal conditions. The films of the 
insert are taken in a separate Petri dish and are kept at 
three different temperatures and humidity condition.  
CONCLUSION  
Ocular insets have been found advantageous as it 
eliminates side effect of pulsed dosing of conventional 
dosage form by providing controlled and sustained drug 
delivery with increase in bioavailability and corneal 
contact time, preventing the loss of drug with better 
patient compliance improving drug efficacy. Various 
classes of ocular insert have been developed till date like 
soluble, insoluble, and bio-degradable ocular insert 
which are further categorized in different types 
depending upon material used and its behavior in drug 
delivery like soluble ocular insert based natural, 
synthetic or semi-synthetic polymer, insoluble ocular 
inserts including diffusion insert, osmotic insert and soft 
contact lenses while bio-erodible involve lacrisert, 
SODI, Minidisc and collagen shield. Non-erodible 
encompasses ocular insert and contact lenses etc. thus 
the ocular insert represent a significant advancement in 
eye ailment. 
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